| 5/20/2022 |
The metastatic cancer drug market size is projected to |
Globe Newswire |
... programs for quick and effective cancer treatment.In 2016, the US Government launched the Cancer Moonshot with three ambitious goals: To accelerate scientific cancer-related discovery, foster greater collaboration, and improve data sharing.The cancer patient community and medical researchers responded with tremendous energy and ingenuity to this campaign.On February 2, 2022, the Cancer Moonshot project was relaunched by highlighting new goals of reducing the death rate of cancer by at ... |
| 5/16/2022 |
Rocket Pharmaceuticals Presents Positive Clinical Data from Danon Disease, Fanconi Anemia and Pyruvate Kinase Deficiency Programs at the 25th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) |
Business Wire |
... They received preventative therapy with a modified immunosuppressive regimen. We believe today’s results represent an important step forward in optimizing the safety of AAV9-based gene therapy for Danon Disease and the Danon patient community . Updated data are anticipated in the third quarter, and we believe that the totality of data from seven patients treated in Phase 1 will support a rapid advance toward a Phase 2 pivotal study ... |
| 5/16/2022 |
BrainStorm Cell Therapeutics Announces First Quarter 2022 Financial Results and Provides a Corporate Update |
PR Newswire |
... here are bolstered by peer-reviewed Phase 3 data that provide evidence of NurOwn's greater treatment effects for ALS patients with less advanced disease, and by our ongoing interactions with the broader physician and patient community . These have allowed us to gain valuable perspective from the world's most prominent thought leaders as we seek NurOwn's optimal path forward. Looking ahead, we will continue to leverage expert feedback as we work ... |
| 5/16/2022 |
Stock Market | Markets |
livermore.com |
... proud of everything our team and partners have accomplished as we continue to make progress on our mission to find a cure for cavernous malformation by bringing together the world’s largest cavernous malformation patient community and the most cutting-edge research. In March, patient enrollment began in Recursion’s REC-994 Phase 2 Clinical Trial , the first drug trial testing a potentially game-changing medicine developed specifically for cavernous ... |
| 5/12/2022 |
International Myeloma Foundation Welcomes Fatima Scipione as Senior Vice President of Strategic Alliances and External Affairs |
PR Newswire |
... and External Affairs.As the Head of Global Oncology Patient Advocacy and Engagement at Takeda Oncology, Scipione led the transformation of patient advocacy—fostering symbiotic partnerships and delivering on the unmet needs of the patient community .Fatima Scipione joins the International Myeloma Foundation (IMF) as Senior Vice President of Strategic Alliances and External Affairs. "I am truly honored and blessed to be able to join this incredible organization and support ... |
| 5/12/2022 |
CALIFORNIA Latino News |
californialatinonews.com |
... support their mission" As the Head of Global Oncology Patient Advocacy and Engagement at Takeda Oncology, Scipione led the transformation of patient advocacy¬ófostering symbiotic partnerships and delivering on the unmet needs of the patient community .Scipione was instrumental in transforming patient advocacy into a strategic function, having led several first-in-class novel initiatives to address important issues affecting the oncology patient community via partnerships with patient organizations, nursing ... |
| 5/10/2022 |
People Who Have Had COVID-19 More Likely to Develop Cardiovascular Disease: New Report Highlights the Need to Refocus on Cardiovascular Care |
Yahoo News |
... cardiovascular disease (CVD). 1 Additional findings show the health burden of CVD is expected to grow due to the long-term implications of COVID-19, highlighting the need to prioritise care for the CVD patient community across European healthcare systems. 1The editorially independent report, published by Economist Impact and sponsored by Daiichi Sankyo Europe, reviewed evidence available to uncover the impact that COVID-19 has had on existing CVD ... |
| 5/10/2022 |
People Who Have Had COVID-19 More Likely to Develop Cardiovascular Disease: New Report Highlights the Need to Refocus on Cardiovascular Care | Business Wire |
Business Wire |
... cardiovascular disease (CVD). 1 Additional findings show the health burden of CVD is expected to grow due to the long-term implications of COVID-19, highlighting the need to prioritise care for the CVD patient community across European healthcare systems. 1The editorially independent report, published by Economist Impact and sponsored by Daiichi Sankyo Europe, reviewed evidence available to uncover the impact that COVID-19 has had on existing CVD ... |
| 5/10/2022 |
MPN Research Foundation and Trialjectory Partner to Provide Advanced Clinical Trial Matching Services for Patients in Need |
PR Newswire |
... cancers, and Trialjectory , the AI-powered decision-support platform for patients, healthcare providers and pharmaceutical companies, today announced a joint collaboration to bring Trialjectory's free, AI-powered clinical trial finder to the MPNRF 's patient community . The clinical trial finder helps match patients with the right trials for their exact diagnosis and increases their access to potentially lifesaving advanced new treatment options as a result.Trialjectory's clinical trial finder uses ... |
| 5/10/2022 |
HLTH announces collaboration with Mercer on New Employer Experience at HLTH 2022 |
PR Newswire |
... the years, attendees at HLTH 2022 will have the ability to personalize their innovation experience and engage with fellow employers, as well as with payers, providers, startups, investors, associations, policymakers, life sciences and the patient community .The Employer Experience at HLTH 2022 will be interwoven throughout the entire event and convene employers at various times to take part in specialty curated content with C-suite panels and deep-dive discussions ... |
| 5/10/2022 |
Catalyst Pharmaceuticals Reports Record First Quarter 2022 |
Globe Newswire |
... converting to FIRDAPSE ® following the removal of Ruzurgi ® from the U. S. market in February 2022. Our accomplishments exemplify our exceptional commercial and patient services capabilities and steadfast commitment to the LEMS patient community that we serve," said Patrick J. McEnany, Chairman and Chief Executive Officer of Catalyst. "We also achieved several meaningful milestones during the quarter, including the issuance of three new patents that we believe position ... |
| 5/9/2022 |
Building and mobilizing your community: Addressing challenges in engaging patients and caregivers |
MedCity News |
Patient advocacy organizations’ main purpose is to provide the resources and education needed to arm all patients as they are navigating a disease. They additionally aspire to be the united voice for their collective patient community , but many organizations are only touching a percentage of their disease community. This becomes a consequential problem since listening to the viewpoints and perspectives of constituents remains vital for all patient advocacy organizations ... |
| 5/5/2022 |
United Rheumatology and CreakyJoints Launch the Rheumatoid Arthritis Wellness Center |
Business Wire |
... for educational information and tools to incorporate into their rheumatoid arthritis (RA) management strategy post-appointment.The Rheumatoid Arthritis Wellness Center digital resources were developed in consultation with health care professionals and the CreakyJoints patient community and overseen by the medical leadership of United Rheumatology. Key topics included in the wellness center include managing fatigue, sleep, exercise, and nutrition as well as recommendations for managing the overall mental and emotional ... |
| 5/2/2022 |
FDA Approves Upadacitinib as Oral Treatment for Adults With Ankylosing Spondylitis |
memesita.com |
The approval of a new drug is welcome news for our patient community .Spinal image of a patient with ankylosing spondylitis. Details: Shutterstock.“The ankylosing spondylitis it is a debilitating disease that often strikes younger adults and over time can cause lasting structural damage that can have an emotional effect on a patient’s life,” said Thomas Hudson, senior vice president, research and development, AbbVie’s chief scientific officer ... |
| 5/2/2022 |
FDA Approves Upadacitinib as Oral Treatment for Adults With Ankylosing Spondylitis |
codelist.biz |
FDA Approves Upadacitinib as Oral Treatment for Adults With Ankylosing SpondylitisThe approval of a new drug is welcome news for our patient community .Spinal image of a patient with ankylosing spondylitis. Details: Shutterstock.“The ankylosing spondylitis it is a debilitating disease that often strikes younger adults and over time can cause lasting structural damage that can have an emotional effect on a patient’s life,” said Thomas Hudson ... |
| 4/29/2022 |
Undiagnosed Patient Organizations Begin Leveraging RARE-X |
PRWeb |
... collaboration and sharing data. Whether empowering rare and undiagnosed patients and their families with genomic information, or building the community through advocacy, networking and support, RUN works to make life easier for the undiagnosed patient community ,” said Gina Szajnuk, co-founder and executive director of the Rare and Undiagnosed Network. “So, when RARE-X came along, it gave us hope. It was a dream for not only my family ... |
| 4/28/2022 |
Remedy Health Media Partners with Belong.Life to Further Enhance Education and Connection Among Cancer and Multiple Sclerosis Patient Communities |
PR Newswire |
... commercial partnership with Belong.Life (Belong), the creator of one of the largest communities of cancer and multiple sclerosis (MS) patients and caregivers, as well as Belong's BOS (Belong Operating Systems), a "build-your-own patient community " platform. The collaboration is forged by the shared missions of Remedy and Belong to improve the quality of life and the quality of care for patients around the world."Belong's mission to improve the ... |
| 4/27/2022 |
Cerner collecting Gaucher disease data in new registry |
Becker's Hospital Review |
... of Neuronopathic Disease) registry. It will collect retrospective and prospective clinical and health outcome data for patients diagnosed with Gaucher disease, according to an April 26 press release.The registry is owned by the patient community , but will be led by Cerner Enviza, an EHR data set.Caregivers will provide their perspective for pediatric and some adult patients, as well as the impact of caring for a family member with ... |
| 4/27/2022 |
2022-04-27 | NDAQ:HRMY | Press Release | Harmony Biosciences Holdings Inc. |
stockhouse.com |
... the initiation of its Phase 3 trial evaluating the efficacy and safety of pitolisant in adult patients with idiopathic hypersomnia (IH), known as the INTUNE study."There has been much interest by both the patient community and healthcare professionals in pitolisant for the treatment of IH and we are excited about the initiation of our Phase 3 INTUNE study in adult patients with this rare neurological disorder," said Harmony's Chief ... |
| 4/27/2022 |
HARMONY BIOSCIENCES INITIATES PHASE 3 TRIAL OF PITOLISANT IN ADULT PATIENTS WITH IDIOPATHIC HYPERSOMNIA |
PR Newswire |
... the initiation of its Phase 3 trial evaluating the efficacy and safety of pitolisant in adult patients with idiopathic hypersomnia (IH), known as the INTUNE study."There has been much interest by both the patient community and healthcare professionals in pitolisant for the treatment of IH and we are excited about the initiation of our Phase 3 INTUNE study in adult patients with this rare neurological disorder," said Harmony's Chief ... |